Entero Healthcare Solutions Ltd
Entero Healthcare Solutions Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Company targets 30% revenue growth for FY26, maintaining full-year guidance despite a softer H1 growth of around 24%; aiming for ~35% growth in H2 to meet this. Entero Healthcare expects strong earnings growth driven by continued revenue growth (~30% guidance for FY26) and margin expansion.
From Entero Healthcare Solutions Ltd's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Company targets 30% revenue growth for FY26, maintaining full-year guidance despite a softer H1 growth of around 24%; aiming for ~35% growth in H2 to meet this.
- Growth driven by three factors: organic growth (13.4% in Q2), full-year impact of past acquisitions, and new acquisitions closing primarily in H2.
- Acquisition strategy focused on higher-margin and high-growth categories like MedTech (currently 14%-15% of business), aiming to increase its share for margin expansion.
- MedTech contributes significantly to growth with 60% of acquisitions this year allocated to this segment.
- Operating cash flow expected to turn positive by year-end, enabling further growth investments.
2 more points from Entero Healthcare Solutions Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Entero Healthcare Solutions Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company is actively pursuing strategic investments, particularly in the MedTech segment, targeting INR1,000 crores in revenue from acquisitions in FY26.
- Significant capital deployment includes acquisitions planned upwards of INR400 crores in the second half of FY26.
- These acquisitions are focused on expanding presence in MedTech (diagnostic consumables, cardiology, orthopaedic devices), and trade generics, aiming for margin enhancement.
- Funding for acquisitions will come from internal accruals, existing cash balances (~INR280 crores), and additional debt if needed.
2 more points from Entero Healthcare Solutions Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Retailing
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Entero Healthcare Solutions Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not explicitly mention a current or expected order book or pending orders in quantified terms.
- However, management discussed a robust pipeline of acquisitions, with approximately 80% of deals expected to close in the second half of FY26, indicating pending deals contributing to future revenue.
- Prabhat Agrawal mentioned closing inorganic deals rapidly in H2 to meet revenue guidance, reflecting a healthy order pipeline.
- The company is actively pursuing attractive MedTech acquisitions, projecting over INR 1,000 crores revenue from MedTech, including INR 600 crores from acquisitions yet to be closed fully.
2 more points from Entero Healthcare Solutions Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Entero Healthcare Solutions Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.9K Cr, net profit ₹45 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Entero Healthcare Solutions Ltd's management said in earlier quarters
Others in Retailing this season
- Matrimony.com Ltd (Q2 FY26)
The company is investing a few crores each quarter experimenting with new initiatives, including AI-based astrology services and adjacent businesses like…
- RattanIndia Enterprises Ltd (Q2 FY26)
2,072 crore, up 18% from Rs. Key investor presentation takeaways from RattanIndia Enterprises Ltd's Q2 FY26 investor presentation — and how it ranks against sec
- Baazar Style Retail Ltd (Q2 FY26)
Planned investment of INR 20-25 crores in FY26 for digital and warehouse transformation, including: . Key concall takeaways from Baazar Style Retail Ltd's Q2…
- Womancart Ltd (Q2 FY26)
Profit: PAT of Rs 530.5 lakhs in H1FY26 with a PAT margin of 10.7%, down slightly from 12.2% in FY25 . Key investor presentation takeaways from Womancart Ltd's
Arthneeti Pro · Annual
Entero Healthcare Solutions Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Entero Healthcare Solutions Ltd Q2 FY26 results?
Company targets 30% revenue growth for FY26, maintaining full-year guidance despite a softer H1 growth of around 24%; aiming for ~35% growth in H2 to meet this. Entero Healthcare expects strong earnings growth driven by continued revenue growth (~30% guidance for FY26) and margin expansion.
What is Entero Healthcare Solutions Ltd share price analysis?
Entero Healthcare Solutions Ltd currently shows a neutral. The stock trades at a P/E of 53.5 with a market cap of ₹6,899 Cr. Investors should review the full earnings analysis for detailed insights.
Is Entero Healthcare Solutions Ltd planning capital expenditure?
The company is actively pursuing strategic investments, particularly in the MedTech segment, targeting INR1,000 crores in revenue from acquisitions in FY26.
Keep Entero Healthcare Solutions Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.